Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450
Ritlecitinib is a moderate inhibitor of CYP3A and CYP1A2. Strong CYP inducers can reduce ritlecitinib concentrations, but not to clinically relevant levels leading to lack of benefit.
Authors
- Martin E. Dowty (ORCID: https://orcid.org/0000-0003-1393-6388)
- Hindu Kalluru
- Anna Plotka
- Yeamin Huh (ORCID: https://orcid.org/0000-0003-0365-4467)
- Vivek S. Purohit (ORCID: https://orcid.org/0000-0002-9019-0789)
- Alexandre Lejeune
- Brian Hee
Institutions
- Pfizer (United States) (US)
- Pfizer (France) (FR)
- Pfizer (India) (IN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1002/bcp.70069
- Citations
- 1
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- Pfizer